A newly described nutrient-sharing pathway
Researchers at Fox Chase Cancer Center have identified a protein that could become a new therapeutic target in pancreatic cancer. Their study, published in Nature Cancer, describes how anoctamin 6, or ANO6, helps pancreatic cancer cells draw cholesterol and other lipids from surrounding support cells.
The work focuses on pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. These tumors grow within an unusually dense tissue environment. Cancer-associated fibroblasts, often called CAFs, make up much of that surrounding tissue and produce collagen-rich structures. The resulting environment can compress functional blood vessels, leaving tumor cells with limited direct access to circulating nutrients.
That raises a basic but consequential question: how do cancer cells obtain materials they need to keep growing when the tumor’s own blood supply is constrained? The Fox Chase team reports that nearby fibroblasts can act as a nutrient source, transferring cholesterol and other lipids to cancer cells.
How the cells exchange cholesterol
According to the researchers, CAFs acquire cholesterol from the bloodstream and pass it to neighboring pancreatic cancer cells through a process called trogocytosis. During this process, cancer cells take small pieces of the fibroblast cell membrane, gaining access to membrane-associated cholesterol and other lipids.
The study identifies ANO6 as an important part of that exchange. Rather than treating fibroblasts as passive material around a tumor, the findings portray them as active participants in sustaining cancer growth. The cells help create the dense pancreatic tumor microenvironment, but they may also provide a route through which cancer cells obtain essential nutrients.
Igor Astsaturov, a professor at Fox Chase and a co-senior author of the study, said the findings help explain how pancreatic cancer cells obtain nutrients despite the distinctive structure of their tumor environment. Co-senior author Edna Cukierman said the laboratory and animal-model work showed that CAF units can serve as a source of these nutrients.
What happened when ANO6 was blocked
The researchers reported that blocking ANO6 slowed tumor growth in preclinical trials and reduced immune suppression. Those two findings are significant because pancreatic cancer is difficult to treat not only because of the cancer cells themselves, but also because of the biological environment around them. A treatment that changes nutrient access and eases immune suppression could potentially affect more than one part of the disease process.
The result does not establish a new treatment for patients. The evidence described comes from laboratory and animal models, and the report presents ANO6 as a potential target rather than a proven clinical therapy. Further research will be needed to determine whether an ANO6-directed approach can be developed safely, whether it has meaningful activity in people, and how it might fit alongside existing pancreatic cancer treatments.
Still, the study offers a clearer biological rationale for pursuing that work. Instead of viewing the fibrotic tissue around pancreatic tumors solely as a barrier, the research suggests it can also be a resource network that tumors exploit.
Why the finding matters
Pancreatic tumors are notable for their dense connective tissue and relatively limited functional blood vessels. In that setting, discovering a mechanism for transferring cholesterol from stromal cells to cancer cells adds detail to scientists’ understanding of tumor metabolism. Cholesterol and other lipids are fundamental cellular materials, and access to them may help tumors persist in an environment where direct nutrient delivery is restricted.
The ANO6 finding also points toward the tumor microenvironment as a treatment opportunity. Rather than aiming only at the malignant cells, a future strategy could attempt to interrupt the support system that helps those cells obtain nutrients and suppress immune activity.
For now, the practical takeaway is narrower but important: Fox Chase researchers have linked ANO6 to a cholesterol-sharing mechanism between fibroblasts and pancreatic cancer cells, and found that blocking the protein produced favorable effects in preclinical models. It is an early-stage result, but one that identifies a specific pathway for follow-up drug-development and translational research.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
